Journal Article

Hormonal carcinogenesis

Brian E. Henderson and Heather Spencer Feigelson

in Carcinogenesis

Volume 21, issue 3, pages 427-433
Published in print March 2000 | ISSN: 0143-3334
Published online March 2000 | e-ISSN: 1460-2180 | DOI: http://dx.doi.org/10.1093/carcin/21.3.427
Hormonal carcinogenesis

More Like This

Show all results sharing this subject:

  • Clinical Cytogenetics and Molecular Genetics

GO

Show Summary Details

Preview

Hormone-related cancers, namely breast, endometrium, ovary, prostate, testis, thyroid and osteosarcoma, share a unique mechanism of carcinogenesis. Endogenous and exogenous hormones drive cell proliferation, and thus the opportunity for the accumulation of random genetic errors. The emergence of a malignant phenotype depends on a series of somatic mutations that occur during cell division, but the specific genes involved in progression of hormone-related cancers are currently unknown. In this review, the epidemiology of endometrial cancer and breast cancer are used to illustrate the paradigms of hormonal carcinogenesis. Then, new strategies for early detection and prevention of hormonal carcinogenesis are discussed. This includes developing polygenic models of cancer predisposition and the further development of safe and effective chemopreventives that block target sequence activity. We developed polygenic models for breast and prostate cancer after hypothesizing that functionally relevant sequence variants in genes involved in steroid hormone metabolism and transport would act together, and also interact with well-known hormonally related risk factors, to define a high-risk profile for cancer. A combination of genes each with minor variation in expressed activity could provide a degree of separation of risk that would be clinically useful as they could yield a large cumulative difference after several decades. The genes included in the breast cancer model are the 17β-hydroxysteroid dehydrogenase 1 (HSD17B1) gene, the cytochrome P459c17α (CYP17) gene, the aromatase (CYP19) gene, and the estrogen receptor alpha (ER) gene. The prostate cancer model includes the androgen receptor gene (AR), steroid 5α-reductase type II (SRD5A2), CYP17 and the 3β hydroxysteroid dehydrogenase (HSD3B2) gene. We present data from our multi-ethnic cohort to support these models.

Keywords: AR, androgen receptor gene; COCs, combined oral contraceptives; CYP17, cytochrome P459c17a gene; E2, estradiol; ER, estrogen receptor alpha gene; HRT, hormone replacement therapy; HSD17B1, 17β-hydroxysteroid dehydrogenase 1 gene; HSD3B2, 3β-hydroxysteroid dehydrogenase gene; OCs, oral contraceptives; OR, odds ratio; RR, relative risk; SHBG, sex hormone-binding globulin; SRD5A2, steroid 5α-reductase type II gene.

Journal Article.  6224 words.  Illustrated.

Subjects: Clinical Cytogenetics and Molecular Genetics

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.